These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4832419)

  • 1. Genotypic variations in Caucasian leukocyte estradiol 16 hydroxylase activity: a measurable determinant of breast cancer risk?
    Lemon HM; Reilly D
    Nebr Med J; 1974 May; 59(5):151-5. PubMed ID: 4832419
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic factors in the etiology of breast cancer.
    Petrakis NL
    Cancer; 1977 Jun; 39(6 Suppl):2709-15. PubMed ID: 326376
    [No Abstract]   [Full Text] [Related]  

  • 3. [Estradiol-2-hydroxylase activity in tumors of the corpus uteri and breast: the effect of smoking].
    Tsyrlina EV; Manikhas (Kolesnik) OS; Vasil'ev DA; Kovalenko IG; Bershteĭn LM
    Vopr Onkol; 2000; 46(3):306-10. PubMed ID: 10976277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic predisposition to carcinoma of the breast: multiple human genotypes for estrogen 16 alpha hydroxylase activity in Caucasians.
    Lemon HM
    J Surg Oncol; 1972; 4(3):255-73. PubMed ID: 5069806
    [No Abstract]   [Full Text] [Related]  

  • 5. Polymorphisms associated with circulating sex hormone levels in postmenopausal women.
    Dunning AM; Dowsett M; Healey CS; Tee L; Luben RN; Folkerd E; Novik KL; Kelemen L; Ogata S; Pharoah PD; Easton DF; Day NE; Ponder BA
    J Natl Cancer Inst; 2004 Jun; 96(12):936-45. PubMed ID: 15199113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated estrogen 16 alpha-hydroxylase activity: is this a genotoxic or nongenotoxic biomarker in human breast cancer risk?
    Nebert DW
    J Natl Cancer Inst; 1993 Dec; 85(23):1888-91. PubMed ID: 8230275
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction and inhibition of estradiol hydroxylase activities in MCF-7 human breast cancer cells in culture.
    Niwa T; Bradlow HL; Fishman J; Swaneck GE
    Steroids; 1990 Jul; 55(7):297-302. PubMed ID: 2219196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased estrogen-16 alpha-hydroxylase activity in women with breast and endometrial cancer.
    Fishman J; Schneider J; Hershcope RJ; Bradlow HL
    J Steroid Biochem; 1984 Apr; 20(4B):1077-81. PubMed ID: 6727352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of estradiol 2- and 16-alpha-hydroxylase activities in MCF-7 human breast cancer cells in culture using radiometric analysis.
    Niwa T; Bradlow HL; Fishman J; Swaneck GE
    J Steroid Biochem; 1989 Aug; 33(2):311-4. PubMed ID: 2770303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk.
    Osborne MP; Bradlow HL; Wong GY; Telang NT
    J Natl Cancer Inst; 1993 Dec; 85(23):1917-20. PubMed ID: 8230281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid hydroxylase induction in cultured human lymphocytes: effects of the menstrual cycle.
    Mason WL; Muijsson-Arnold IE; McKenzie M; Cantrell ET; Busbee DL
    Steroids; 1978 Jan; 31(1):1-7. PubMed ID: 663955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholanoic acids and cholesterol 7-alpha-hydroxylase activity in human leucocytes.
    Dodd NK; Sizer CE; Dupont J
    Biochem Biophys Res Commun; 1982 May; 106(2):385-9. PubMed ID: 7103999
    [No Abstract]   [Full Text] [Related]  

  • 13. Aromatase regulation and breast cancer.
    Reed MJ; Purohit A
    Clin Endocrinol (Oxf); 2001 May; 54(5):563-71. PubMed ID: 11380485
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer.
    Watanabe J; Shimada T; Gillam EM; Ikuta T; Suemasu K; Higashi Y; Gotoh O; Kawajiri K
    Pharmacogenetics; 2000 Feb; 10(1):25-33. PubMed ID: 10739169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk.
    Taioli E; Bradlow HL; Garbers SV; Sepkovic DW; Osborne MP; Trachman J; Ganguly S; Garte SJ
    Cancer Detect Prev; 1999; 23(3):232-7. PubMed ID: 10337002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of urokinase plasminogen activator (uPA) in the leukocytes and tissues of patients with benign and malignant breast lesions.
    Barberi S; Montagna G; Rossi L
    Breast Dis; 2019; 38(1):15-23. PubMed ID: 30562887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer.
    Bailey LR; Roodi N; Dupont WD; Parl FF
    Cancer Res; 1998 Nov; 58(22):5038-41. PubMed ID: 9823305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
    Haiman CA; Hankinson SE; Spiegelman D; Colditz GA; Willett WC; Speizer FE; Kelsey KT; Hunter DJ
    Cancer Res; 1999 Mar; 59(5):1015-20. PubMed ID: 10070957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of estradiol by human breast cancer.
    Abul-Hajj YJ; Thijssen JH; Blankenstein MA
    Eur J Cancer Clin Oncol; 1988 Jul; 24(7):1171-8. PubMed ID: 3416901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.
    Jernström H; Vesprini D; Bradlow HL; Narod SA
    J Natl Cancer Inst; 2001 Apr; 93(7):554-5. PubMed ID: 11287451
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.